Literature DB >> 8843221

Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group.

M E Brandt1, M A Pfaller, R A Hajjeh, E A Graviss, J Rees, E D Spitzer, R W Pinner, L W Mayer.   

Abstract

Serial isolates of Cryptococcus neoformans from 33 human immunodeficiency virus-infected patients with cryptococcosis were analyzed to determine whether persistence might result from reinfection with a new cryptococcal strain or acquisition of antifungal resistance. Isolates were subtyped by multilocus enzyme electrophoresis (MEE), electrophoretic karyotyping (EK), random-amplified polymorphic DNA (RAPD), and the CNRE-1 DNA probe, MICs of amphotericin B, fluconazole, and 5-fluorocytosine were determined. No changes in MEE or RAPD subtypes were detected in serial isolates from any patient. Isolates from 8 patients (24%) showed alterations in EK only (mobility change in two or more bands) but not with any other subtyping method. MICs did not change significantly in isolates from 30 patients. In 1 case, the fluconazole MIC increased stepwise over 18 months, suggesting development of resistance. These overall invariant subtyping and MIC results confirm previous studies suggesting that persistent cryptococcal infection is due to relapse rather than reinfection or antifungal drug resistance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8843221     DOI: 10.1093/infdis/174.4.812

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  28 in total

Review 1.  The ins and outs of DNA fingerprinting the infectious fungi.

Authors:  D R Soll
Journal:  Clin Microbiol Rev       Date:  2000-04       Impact factor: 26.132

2.  It infects me, it infects me not: phenotypic switching in the fungal pathogen Cryptococcus neoformans.

Authors:  C A D'Souza; J Heitman
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

3.  Molecular epidemiology of Cryptococcus neoformans in Brazil and the United States: evidence for both local genetic differences and a global clonal population structure.

Authors:  S P Franzot; J S Hamdan; B P Currie; A Casadevall
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

4.  Cryptococcal Meningitis in HIV-Infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.725

5.  Clinical Trichophyton rubrum strain exhibiting primary resistance to terbinafine.

Authors:  Pranab K Mukherjee; Steven D Leidich; Nancy Isham; Ingrid Leitner; Neil S Ryder; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 6.  Phenotypic switching and its implications for the pathogenesis of Cryptococcus neoformans.

Authors:  Neena Jain; Abraham Guerrero; Bettina C Fries
Journal:  FEMS Yeast Res       Date:  2006-06       Impact factor: 2.796

7.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

8.  In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans.

Authors:  T Yamazumi; M A Pfaller; S A Messer; A Houston; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

9.  Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.

Authors:  M E Brandt; M A Pfaller; R A Hajjeh; R J Hamill; P G Pappas; A L Reingold; D Rimland; D W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

10.  Clonal reproduction and limited dispersal in an environmental population of Cryptococcus neoformans var gattii isolates from Australia.

Authors:  C L Halliday; D A Carter
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.